Drugs / Anti-Thyroglobulin mTCR PBL
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02390739 | Mar 2015 → Mar 2017 | thyroid cancer | National Cancer Institute (NCI) | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-Thyroglobulin mTCR PBL | “Biological: Anti-Thyroglobulin mTCR PBL” NCT02390739 ↗ |
| Route | Intravenous | “cells will be infused intravenously (IV) over 20 to 30 minutes” NCT02390739 ↗ |